Core Insights - Teladoc reported revenue of $626.44 million for the quarter ended September 2025, a decrease of 2.2% year-over-year, with an EPS of -$0.21 compared to -$0.19 in the same quarter last year [1] - The revenue exceeded the Zacks Consensus Estimate of $625.02 million by 0.23%, while the EPS surprised positively by 19.23% against the consensus estimate of -$0.26 [1] Financial Performance Metrics - Average Monthly Revenue Per U.S. Integrated Care Member was $1.27, matching analyst estimates [4] - BetterHelp Paying Users totaled 0.38 million, slightly below the estimated 0.39 million [4] - U.S. Integrated Care Members reached 102.5 million, exceeding the average estimate of 102.26 million [4] - Chronic Care Program Enrollment was 1.17 million, slightly above the estimate of 1.16 million [4] Revenue by Segment - Integrated Care revenue was $389.54 million, surpassing the estimate of $388.13 million, reflecting a year-over-year increase of 1.5% [4] - BetterHelp revenue was $236.9 million, below the estimate of $237.7 million, indicating a year-over-year decline of 7.8% [4] - BetterHelp-Other Wellness Services generated $5.1 million, compared to the estimate of $5.28 million, representing an 18.5% year-over-year decrease [4] - BetterHelp-Therapy Services revenue was $231.8 million, slightly below the estimate of $231.99 million, showing a 7.5% decline year-over-year [4] Revenue by Type - Other revenue amounted to $105.53 million, exceeding the estimate of $90.63 million, with a year-over-year increase of 23.8% [4] - Access fees revenue was $520.91 million, below the estimate of $533.92 million, reflecting a 6.2% year-over-year decline [4] Adjusted EBITDA - Adjusted EBITDA for BetterHelp was $3.84 million, significantly lower than the average estimate of $8.46 million [4] - Adjusted EBITDA for Integrated Care was $66.07 million, exceeding the estimate of $59.01 million [4] Stock Performance - Teladoc shares returned +8.2% over the past month, outperforming the Zacks S&P 500 composite's +3.8% change [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]

Core Insights - Teladoc (TDOC) reported a quarterly loss of $0.21 per share, better than the Zacks Consensus Estimate of a loss of $0.26, representing an earnings surprise of +19.23% [1] - The company generated revenues of $626.44 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 0.23%, although this is a decline from $640.51 million in the same quarter last year [2] - Teladoc has outperformed consensus EPS estimates three times over the last four quarters and has topped revenue estimates four times in the same period [2] Financial Performance - The company has shown a favorable trend in estimate revisions ahead of the earnings release, leading to a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] - Current consensus EPS estimate for the upcoming quarter is -$0.19 on revenues of $636.73 million, while for the current fiscal year, the estimate is -$1.17 on revenues of $2.52 billion [7] Market Context - Teladoc shares have declined approximately 8% since the beginning of the year, contrasting with the S&P 500's gain of 17.2% [3] - The Medical Services industry, to which Teladoc belongs, is currently ranked in the top 39% of over 250 Zacks industries, suggesting a favorable industry outlook [8]

Group 1 - The article does not provide any specific content or key points related to a company or industry [1]

Financial Data and Key Metrics Changes - Consolidated revenue for Q3 2025 was $626 million, a decline of 2.2% year over year, with adjusted EBITDA of $70 million representing an 11.2% margin [16][17] - Net loss per share was $0.28, which included a non-cash goodwill impairment charge of $0.07 per share pre-tax [16][17] - Free cash flow was $68 million in Q3, bringing year-to-date free cash flow to $113 million, with cash and cash equivalents at $726 million, an increase of $47 million sequentially [17][25] Business Line Data and Key Metrics Changes - Integrated Care revenue was $390 million, up 1.5% year over year, with U.S. Integrated Care membership at 102.5 million, a 9% increase year over year [17][18] - Chronic care program enrollment grew 4% sequentially, reaching 1.17 million [18] - BetterHelp segment revenue was $236.9 million, with average paying users declining 4% year over year to 382,000 [19][20] Market Data and Key Metrics Changes - International integrated care revenues grew 14% year over year on a constant currency basis [12] - The acquisitions of Catapult and Telecare contributed approximately 245 basis points to Integrated Care segment growth [18] Company Strategy and Development Direction - The company is focusing on integrated care, emphasizing performance, innovation, and client impact, with over 100 million people having access to its services [4][8] - The shift towards fee-for-service visit models is evident, with visit-based revenues now comprising over 50% of U.S. virtual care revenues [8] - The company aims to leverage its scaled mental health position and is excited about the new employee assistance program offering called Wellbound [9][10] Management's Comments on Operating Environment and Future Outlook - Management acknowledged substantial challenges in healthcare, including affordability, rising costs, and unmet mental health needs, while expressing commitment to driving the next evolution of virtual care [14][15] - The company expects 2025 consolidated revenue of $2.510 billion to $2.539 billion and adjusted EBITDA of $270 million to $287 million, with a focus on maintaining strong cash flow generation [21][24] Other Important Information - The company achieved ISO 9001 certification for key processes within U.S. integrated care, reflecting operational excellence [12] - The company was recognized as one of Time magazine's top health tech companies of 2025, highlighting its innovative contributions to healthcare [26] Q&A Session Summary Question: Insights on 2026 Selling Season - Management characterized 2025 as a repositioning year, focusing on driving higher performance and product innovation, with positive discussions with clients regarding new products and services for 2026 [29][30][32] Question: BetterHelp Margins and Transition to Insurance - Management indicated that BetterHelp margins are impacted by the transition to insurance offerings, with expectations for improved margins as the insurance business scales [34][36][67] Question: Chronic Care Enrollment Trends - Management expressed satisfaction with the sequential growth in chronic care enrollment and highlighted opportunities for further engagement and clinical interventions [78][81]

Financial Performance - Q3 2025 - Revenue for 3Q-25 was $626 million, a decrease of 2% year-over-year[4] - Net loss per share for 3Q-25 was $(0.28)[4] - Adjusted EBITDA for 3Q-25 was $69.9 million, a decrease of 16% year-over-year[4] Financial Outlook - FY25 - The company projects FY-25 revenue to be in the range of $2,510 million to $2,539 million[5] - The company projects FY-25 net loss per share to be in the range of $(1.25) to $(1.10)[5] - The company projects FY-25 Adjusted EBITDA to be in the range of $270 million to $287 million[5] Financial Outlook - Q4 2025 - The company projects 4Q-25 revenue to be in the range of $622 million to $652 million[5] - The company projects 4Q-25 net loss per share to be in the range of $(0.25) to $(0.10)[5] - The company projects 4Q-25 Adjusted EBITDA to be in the range of $73 million to $90 million[5] Balance Sheet and Cash Flow - Cash and cash equivalents as of September 30, 2025, were $726 million[36] - Convertible senior notes as of September 30, 2025, were $994 million[36] - Operating cash flow for 3Q-25 was $99 million[36] - Free cash flow for 3Q-25 was $68 million[36]

Core Insights - Teladoc Health, Inc. reported a 2% decrease in revenue for Q3 2025, totaling $626.4 million compared to $640.5 million in Q3 2024, with a net loss of $49.5 million or $0.28 per share [5][6][8] - The company continues to focus on strategic priorities, including growth initiatives in the Integrated Care segment and the rollout of insurance acceptance in BetterHelp [3] Financial Performance - Revenue for Q3 2025 was $626.4 million, down 2% from $640.5 million in Q3 2024; access fees revenue decreased 6% to $520.9 million, while other revenue increased 24% to $105.5 million [5][32] - U.S. revenue decreased 5% to $509.8 million, while international revenue increased 12% to $116.7 million [5][32] - Integrated Care segment revenue increased 2% to $389.5 million, while BetterHelp segment revenue decreased 8% to $236.9 million [5][36] Loss and Adjusted EBITDA - Net loss for Q3 2025 was $49.5 million, compared to a loss of $33.3 million in Q3 2024; adjusted EBITDA decreased 16% to $69.9 million [6][10] - The Integrated Care segment's adjusted EBITDA decreased 3% to $66.1 million, while BetterHelp's adjusted EBITDA decreased 75% to $3.8 million [10][36] Nine-Month Performance - For the first nine months of 2025, revenue decreased 2% to $1.887 billion from $1.929 billion in the same period of 2024 [11] - Net loss for the first nine months of 2025 was $175.2 million, significantly improved from a loss of $952.8 million in the same period of 2024 [12] Cash Flow and Capital Expenditures - Cash flow from operations was $99.3 million in Q3 2025, down from $110.2 million in Q3 2024; free cash flow was $67.9 million compared to $79.0 million in Q3 2024 [16] - Capital expenditures for Q3 2025 were $31.3 million, slightly up from $31.1 million in Q3 2024 [16] Financial Outlook - For the full year 2025, the company expects revenue between $2.510 billion and $2.539 billion, with adjusted EBITDA between $270 million and $287 million [19][20] - The fourth quarter of 2025 is projected to have revenue between $622 million and $652 million, with adjusted EBITDA between $73 million and $90 million [21]

Financial Performance - For Q3 2025, Teladoc Health reported consolidated revenue of $626.4 million and adjusted EBITDA of $69.9 million[3] - The net loss for the three months ended September 30, 2025, was $49.5 million, compared to a net loss of $33.3 million in Q3 2024[18] - The company reaffirmed its full-year 2025 consolidated revenue and adjusted EBITDA outlook previously issued on July 29, 2025[3] - Adjusted EBITDA for Q3 2025 included total adjustments of $119.4 million, which comprised various costs such as stock-based compensation and goodwill impairments[18] - Teladoc Health emphasizes the importance of adjusted EBITDA as a key measure of performance, excluding certain non-recurring items[9] - The preliminary financial results are subject to change and should not be viewed as a substitute for full financial statements prepared in accordance with GAAP[5] Management Changes - The company is currently searching for a new Chief Financial Officer following the announcement of Mala Murthy's departure[2] Future Outlook - Forward-looking statements indicate potential uncertainties regarding future financial performance and market conditions[6] - The company will host a conference call on October 29, 2025, to discuss its Q3 2025 financial results[4] Strategic Goals - The company aims to enhance access to virtual care and improve health outcomes through its relationships with various stakeholders[19]

Core Insights - Teladoc (TDOC) shares increased by 10% to close at $9.46, driven by higher trading volume compared to typical sessions, and an overall gain of 8.2% over the past four weeks [1][2] Financial Performance - The company anticipates third-quarter revenue of $626.4 million, exceeding the Zacks Consensus Estimate of $625 million, with adjusted EBITDA projected at $69.9 million [2] - The expected quarterly loss is $0.26 per share, reflecting a year-over-year decline of 36.8%, while revenues are forecasted to be $625.2 million, down 2.4% from the previous year [3] Earnings Estimates - The consensus EPS estimate for the quarter has been revised 0.6% higher in the last 30 days, indicating a positive trend that typically correlates with stock price appreciation [4] - Empirical research suggests that trends in earnings estimate revisions are strongly linked to near-term stock price movements [3] Market Position - Teladoc holds a Zacks Rank of 2 (Buy), indicating a favorable outlook compared to other stocks in the medical services industry [5] - In contrast, Avantor, a peer in the same industry, has a Zacks Rank of 4 (Sell) and has seen a 2.2% decrease in its EPS estimate over the past month [6]

Core Viewpoint - Teladoc Health's stock price increased by over 9%, reaching $9.398, following updates from several Wall Street firms on its rating and target price [1] Summary by Category Stock Performance - Teladoc Health's stock rose more than 9% to $9.398 as of the report [1] Analyst Ratings - Multiple major Wall Street firms updated their ratings for Teladoc Health, with target prices ranging from $9 to $12 [1] - Bank of America analyst Allen Lutz maintained a "Hold" rating and raised the target price from $8.5 to $9 [1]

Core Viewpoint - Teladoc Health's stock price increased by over 9%, reaching $9.398, following updates from several major Wall Street firms on its rating and target price [1] Summary by Category Stock Performance - Teladoc Health's stock rose more than 9% to $9.398 as of the latest report [1] Analyst Ratings - Multiple Wall Street firms have updated their ratings for Teladoc Health, with target prices ranging from $9 to $12 [1] - Bank of America analyst Allen Lutz maintained a hold rating and raised the target price from $8.5 to $9 [1]